Last reviewed · How we verify
Gemcitabine + Rituximab
Gemcitabine damages cancer cell DNA while rituximab targets and eliminates B cells expressing CD20, combining chemotherapy with immunotherapy.
Gemcitabine damages cancer cell DNA while rituximab targets and eliminates B cells expressing CD20, combining chemotherapy with immunotherapy. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | Gemcitabine + Rituximab |
|---|---|
| Sponsor | CTI BioPharma |
| Drug class | Chemotherapy + monoclonal antibody combination |
| Target | Ribonucleotide reductase (gemcitabine); CD20 (rituximab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing strand breaks and apoptosis in rapidly dividing cells. Rituximab is a chimeric monoclonal antibody against CD20 that depletes B cells through antibody-dependent cellular cytotoxicity and direct induction of apoptosis. Together, they provide synergistic cytotoxic and immunologic effects against B-cell malignancies.
Approved indications
- B-cell non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Anemia
- Infusion reactions
- Nausea and vomiting
- Fatigue
- Infections
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy (PHASE2)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine + Rituximab CI brief — competitive landscape report
- Gemcitabine + Rituximab updates RSS · CI watch RSS
- CTI BioPharma portfolio CI